Back to Search Start Over

OIP5-AS1 contributes to the development in endometrial carcinoma cells by targeting miR-152-3p to up-regulate SLC7A5.

Authors :
Liang, Minglin
Wang, Hongbo
Liu, Cong
Lei, Tao
Min, Jie
Source :
Cancer Cell International. 8/21/2021, Vol. 21 Issue 1, p1-10. 10p.
Publication Year :
2021

Abstract

Background: Endometrial carcinoma (EC) is one common gynecological tumor, threatening physical and psychological health of females. Huge amount of essays indicated that long non-coding RNAs (lncRNAs) were widely reported to serve as a crucial regulator in the biological movements among multiple carcinomas, including EC. Methods: RT-qPCR was implemented to detect the expression of target genes. Loss/gain-of-function experiments certified the impacts of OIP5-AS1 and miR-152-3p on EC cell progression. Results: Data of this research suggested that powerful expression of OIP5-AS1 was discovered in EC cell lines. Loss/gain-of-function assays inferred that OIP5-AS1 promoted proliferative, migratory and invasive abilities, and Epithelial-Mesenchymal Transition (EMT). In addition, we identified miR-152-3p expression was negatively modulated by OIP5-AS1. OIP5-AS1 accelerated the development of EC cells via downregulating miR-152-3p expression. SLC7A5 was selected out as a downstream target of miR-152-3p. The competing relationship between OIP5-AS1 and SLC7A5 was corroborated by luciferase reporter assay. Eventually, the results of rescue assays indicated that SLC7A5 overexpression could restore the impacts of OIP5-AS1 ablation on the progression of EC cells. Conclusion: Our research confirmed that OIP5-AS1 propeled the development of EC cells through targeting miR-152-3p/SLC7A5. OIP5-AS1 could be utilized as a target for EC treatment. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14752867
Volume :
21
Issue :
1
Database :
Academic Search Index
Journal :
Cancer Cell International
Publication Type :
Academic Journal
Accession number :
152026424
Full Text :
https://doi.org/10.1186/s12935-021-02061-0